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Molecular characterization of extended-spectrum b-lactamaseproducing Shigella isolates from humans in South Africa, 2003 Africa, -2009 Bacillary dysentery is an important cause of acute diarrhoeal disease in poor communities and species of the genus Shigella are among the aetiological agents of this disease, causing an estimated 165 million infections annually with 1.1 million associated deaths (Vinh et al., 2009) . Shigella flexneri serotype 2a is the predominant pathogen responsible for bacillary dysentery in developing countries (Huang et al., 2005) . Due to their ability to acquire mobile genetic elements, such as resistance plasmids and transposons, species of the genus Shigella have progressively acquired resistance to antimicrobials that are used in treatment of bacillary dysentery (Vinh et al., 2009) . The production of b-lactamases is one of the most effective and widespread mechanisms used by Gram-negative bacteria to circumvent the bactericidal effect of antimicrobials (Essack et al., 2001) . In members of the family Enterobacteriaceae, extended-spectrum blactamase (ESBL) and AmpC b-lactamase production are important mechanisms of resistance to b-lactam antimicrobials such as ceftriaxone, ceftazidime and cefotaxime (Kruger et al., 2004) . ESBL and AmpC b-lactamase production is often associated with resistance to other classes of antimicrobials and, as a result, antimicrobial treatment of ESBLproducing isolates becomes limited (Carattoli, 2009) . Dysentery caused by ESBL-and AmpC b-lactamase-producing species of the genus Shigella is seen relatively infrequently (Vinh et al., 2009) . In South Africa, ESBLs have been previously identified in members of the family Enterobacteriaceae, including members of the genera Salmonella (Kruger et al., 2004) and Klebsiella (Essack et al., 2001) . However, after a PubMed literature search, we could find no published data regarding the genotypic description of ESBL-producing strains of the genus Shigella isolated in South Africa. Due to the importance of this disease in developing countries, we were prompted to genotypically characterize ESBL production in strains of the genus Shigella isolated in South Africa during [2003] [2004] [2005] [2006] [2007] [2008] [2009] (CLSI, 2009) . Phenotypic detection of ESBL production was carried out using the combination disc diffusion screening method based on the inhibitory effect of clavulanic acid (Mast Group).
Genetic relatedness between the Shigella isolates was investigated by using PFGE using PulseNet protocols (Ribot et al., 2006) . ESBL (bla TEM , bla SHV and bla CTX-M ) and AmpC b-lactamase (bla CMY ) genotypes were determined using PCR as described previously (Essack et al., 2001; Liebana et al., 2006; Rankin et al., 2005) . Positive controls for PCR included the following strains: Klebsiella pneumoniae ATCC 51503, K. pneumoniae ATCC 700603 and K. pneumoniae D-17. PCR products were sequenced using a BigDye Terminator Cycle Sequencing kit (Applied Biosystems) and an Applied Biosystems 3130 genetic analyser. DNA sequences were analysed using DNASTAR Lasergene (version 8.0) software and the identities of DNA sequences were determined by BLAST analysis using the BLASTN algorithm at the National Center for Biotechnology Information (NCBI) website (http://blast.ncbi.nlm.nih.gov/Blast.cgi).
Of the 6833 isolates, 21 (0.3 %) were identified as ESBL-producing. One isolate was no longer viable; therefore, only 20 isolates were available for further analysis. Sixteen of the isolates were obtained from stool samples and four isolates were obtained from blood samples (Table 1) . Patient ages ranged from 4 months to 54 years. The most commonly encountered species was Shigella flexneri (15/20, 75.0 %), represented by the following serotypes: S. flexneri 2a (7/20, 35 %), S. flexneri 6 (5/20, 25 %), S. flexneri 3b (2/20, 10 %) and S. flexneri 1b (1/20, 5 %). The remaining five isolates were identified as Shigella sonnei phase II (4/20, 20 %) and Shigella dysenteriae 3 (1/20, 5 %). These data are in agreement with the distribution of Shigella serotypes in developing countries (Huang et al., 2005) . All 20 isolates were resistant to ampicillin, amoxicillin/clavulanic acid and sulfamethoxazole/trimethoprim. The 17 isolates tested with imipenem were all susceptible. All isolates were susceptible to ciprofloxacin and all but one (strain 5) were susceptible to nalidixic acid. For most of the 20 isolates, the MIC of cefotaxime was approximately eightfold greater than that of ceftazidime (Table 1) . This phenotype is suggestive of CTX-M-type b-lactamase production (Mushtaq et al., 2003) .
Based on PFGE analysis, all the isolates were unrelated (data not shown). PCR and DNA sequencing revealed that 16 out of the 20 isolates were positive for the bla TEM-1 b-lactamase gene, the most commonly encountered b-lactamase gene in members of the family Enterobacteriaceae, characterized by high hydrolytic activity against penicillins and early cephalosporins such as cephalothin and cephaloridine (Bradford, 2001) . The CTX-M-type b-lactamase gene was the most commonly identified ESBL via PCR analysis, with DNA sequencing identifying bla CTX-M-15 in 18 isolates and bla CTX-M-14 in one isolate (Table 1) . These data are in agreement with worldwide data, which describe bla CTX-M-15 and bla CTX-M-14 as the most common genes encoding CTX-M-type b-lactamases identified in members of the genus Shigella (Mushtaq et al., 2003; Huang et al., 2005) . Members of the family Enterobacteriaceae that produce CTX-M-type b-lactamases are a major cause of disease outbreaks and sporadic infections worldwide (Mushtaq et al., 2003) . These enzymes preferentially hydrolyse cefotaxime rather than ceftazidime. Even so, reports have indicated that bla CTX-M-15 -encoded enzymes show more activity against ceftazidime than do other bla CTX-M gene derivatives and that point mutations in the active site of CTX-M-type b-lactamases can increase their activity against this b-lactam (Mushtaq et al., 2003) . The bla CTX-M-15 gene has been reported to coexist on the same plasmid with the bla TEM-1 gene (Carattoli, 2009) ; this correlates well with the results of the current study, which showed that all the isolates that possessed the bla TEM-1 gene also possessed the bla CTX-M 15 gene (with the exception of the single nalidixic acidresistant isolate, strain 5; see Table 1 ). Only one of the ESBL-producers from this study was PCR-positive for the SHV-type b-lactamase, which is encoded by the bla SHV-2 gene. This ESBL displays extended-spectrum activity towards oxyiminocephalosporins and aztreonam (Bradford, 2001) .
Six out of the 20 ESBL-producing isolates were PCR-positive for the CMY-type b-lactamase, which is encoded by the bla CMY-2 gene. This enzyme has been reported in isolates of S. sonnei from Taiwan and is the most commonly encountered plasmid-borne AmpC b-lactamase worldwide (Huang et al., 2005) . The bla CMY-2 gene confers bacterial resistance to penicillins, cephalosporins and aztreonam (Rankin et al., 2005) . Unlike ESBLs, AmpC b-lactamases, such as those encoded by the bla CMY gene, are not inhibited by b-lactamase inhibitors, such as clavulanic acid and tazobactum, and Correspondence there is currently no standardized method for identification in the clinical laboratory, although AmpC b-lactamase screening methods using boronic acid have been reported (Jeong et al., 2009) . If isolates that are bla CMY -positive and ESBL-negative exist, they may be missed by current diagnostic methods. Such failures in the identification of CMY-type b-lactamase producers may lead to inappropriate antimicrobial treatment, which may result in increased mortality rates (Mushtaq et al., 2003) . It has also been reported that the presence of an ESBL can be masked by the expression of an AmpC b-lactamase, leading to misinterpreted results in isolates where both these types of b-lactamase are produced (Rankin et al., 2005) .
It is not uncommon for members of the family Enterobacteriaceae to carry multiple b-lactamase genes (Huang et al., 2005) . This was also true of the isolates described in the current study, most of which carried multiple b-lactamase genes, including: bla TEM-1 , bla SHV-2 and bla CTX-M-15 (n51); bla TEM-1 , bla CTX-M-15 and bla CMY-2 (n55); bla TEM-1 and bla CTX-M-15 (n59); and bla TEM-1 and bla CMY-2 (n51). It has been reported that carriage of multiple b-lactamase genes could lead to limited b-lactam therapeutic options (Rankin et al., 2005) .
The results of the current study show that bla CTX-M-15 was the most commonly identified ESBL associated with resistance to ESBL antimicrobials in South African isolates of Shigella. The majority of the ESBL-producing isolates harboured the bla CTX-M-15 gene, which is carried on plasmids and can be disseminated via horizontal gene transfer to other Gramnegative pathogens (Carattoli, 2009; Liebana et al., 2006 ). In the current study, a series of ESBL-producing Shigella isolates from South Africa have been identified, which, although comprising ,1 % of all the isolates obtained for surveillance, are clinically relevant as they represent a challenge in disease management and patient treatment. The emergence of CTX-M-type b-lactam-producing isolates of the genus Shigella in South Africa is of great concern; therefore, continued surveillance is needed to monitor further incidences of these isolates.
